The anti-HIV injection will be made in SA: Here are 4 benefits of the ... - Bhekisisa
CAB-LA, a long-acting HIV prevention shot is currently being trailed in 3 200 women across Sub-Saharan Africa. (Yolanda Mdzeke, Bhekisisa) The two-monthly HIV prevention injection, CAB-LA, will be made in South Africa, at the Indian drug company Cipla's Benoni and Durban plants. But a start date for production hasn't yet been announced. Cipla is one of three Indian pharmaceutical companies who have been granted licences to produce cheaper, generic versions of ViiV Healthcare's branded product. CAB-LA can virtually wipe out someone's chances of contracting HIV through sex, but because it's complex to manufacture and companies would need to implement and be trained on new technology, it could take between three and five years for generic products to become available. We look at the process and break down why intellectual property agreements and technology transfer are crucial to get medicines to people who need them most. Although a sta